LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

Search

Relay Therapeutics Inc

Fermé

SecteurSoins de santé

2.87 -6.21

Résumé

Variation du prix de l'action

24h

Actuel

Min

2.78

Max

2.97

Chiffres clés

By Trading Economics

Revenu

-1.1M

-77M

Ventes

7.7M

7.7M

BPA

-0.455

Marge bénéficiaire

-1,003.581

Employés

259

EBITDA

-1.2M

-85M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+377.82% upside

Dividendes

By Dow Jones

Prochains Résultats

5 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-52M

502M

Ouverture précédente

9.08

Clôture précédente

2.87

Sentiment de l'Actualité

By Acuity

50%

50%

179 / 382 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bearish Evidence

Relay Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

20 mai 2025, 20:54 UTC

Acquisitions, Fusions, Rachats

PNC to Buy Private-Equity Agent Aqueduct Capital

20 mai 2025, 20:50 UTC

Résultats

Palo Alto Networks Posts Higher 3Q Sales, Profit Slips

20 mai 2025, 23:48 UTC

Acquisitions, Fusions, Rachats

Kraft Heinz Evaluating Strategic Transactions, Berkshire Hathaway Steps Away From Board -- Update

20 mai 2025, 23:42 UTC

Market Talk

Nikkei May Trade Rangebound Amid Tariff Uncertainty -- Market Talk

20 mai 2025, 23:39 UTC

Market Talk

Gold Steady, Supported by Lingering U.S. Fiscal-Deficit Concerns -- Market Talk

20 mai 2025, 23:08 UTC

Market Talk

James Hardie's Repair & Remodel Outlook Surprises RBC -- Market Talk

20 mai 2025, 22:46 UTC

Acquisitions, Fusions, Rachats

Gold Road: Takeover Remains Subject to Independent Expert Findings; Shareholder, Court Approval

20 mai 2025, 22:45 UTC

Acquisitions, Fusions, Rachats

Gold Road: Notified Australia Government Has No Objections to Takeover by Gold Fields

20 mai 2025, 22:44 UTC

Actualités

Venezuela Frees U.S. Air Force Veteran in Overture to Trump -- 2nd Update

20 mai 2025, 22:20 UTC

Actualités

In Latest EV Pullback, Ford to Share Battery Plant With Nissan -- WSJ

20 mai 2025, 22:00 UTC

Résultats

ZTO Express (Cayman) 1Q Adj EPS 37c >ZTO

20 mai 2025, 22:00 UTC

Résultats

ZTO Express (Cayman) 1Q EPS 34c >ZTO

20 mai 2025, 22:00 UTC

Résultats

ZTO Express (Cayman) 1Q Rev $1.5B >ZTO

20 mai 2025, 21:44 UTC

Résultats

James Hardie Industries 4Q Adj EPS 36c >JHX

20 mai 2025, 21:44 UTC

Résultats

James Hardie Industries: Sees FY26 North America Net Sales Growth Up Low Single Digits >JHX

20 mai 2025, 21:44 UTC

Résultats

James Hardie Industries 4Q EPS 10c >JHX

20 mai 2025, 21:44 UTC

Résultats

James Hardie Industries 4Q Sales $972M >JHX

20 mai 2025, 20:52 UTC

Actualités

Elon Musk to Cut Back Political Spending -- 3rd Update

20 mai 2025, 20:52 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20 mai 2025, 20:52 UTC

Market Talk

Mexican Stocks Near Record High As Trade Concerns Ease -- Market Talk

20 mai 2025, 20:30 UTC

Acquisitions, Fusions, Rachats

PNC Financial: Aqueduct Acquisition Expected to Close in Mid-Summer, Terms Won't be Disclosed >PNC

20 mai 2025, 20:28 UTC

Acquisitions, Fusions, Rachats

PNC Bank Agrees To Acquire Aqueduct Capital Group To Complement Harris Williams Capabilities >PNC

20 mai 2025, 20:23 UTC

Acquisitions, Fusions, Rachats

Tesla CEO Musk Says He Plans to Be at White House for a Couple Days Every Few Weeks

20 mai 2025, 20:22 UTC

Résultats

XP 1Q Adj EPS BRL2.29 >XP

20 mai 2025, 20:22 UTC

Résultats

XP 1Q Rev BRL4.345B >XP

20 mai 2025, 20:21 UTC

Acquisitions, Fusions, Rachats

Tesla CEO Musk: 'We're in the Big Bang of Intelligence Explosion'

20 mai 2025, 20:20 UTC

Actualités

Fed's Bostic Signals Longer Delay in Cutting Interest Rates -- Barrons.com

20 mai 2025, 20:19 UTC

Acquisitions, Fusions, Rachats

Tesla CEO Musk Says He Doesn't Currently Have Plans to Merge Tesla, xAI

20 mai 2025, 20:11 UTC

Actualités

Venezuela Frees U.S. Air Force Veteran in Overture to Trump -- Update

20 mai 2025, 20:09 UTC

Résultats

Palo Alto Networks 3Q Remaining Performance Obligation $13.5 B >PANW

Comparaison

Variation de prix

Relay Therapeutics Inc prévision

Objectif de Prix

By TipRanks

377.82% hausse

Prévisions sur 12 Mois

Moyen 14 USD  377.82%

Haut 23 USD

Bas 4 USD

Basé sur 12 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

12 ratings

10

Achat

2

Maintien

0

Vente

Score Technique

By Trading Central

2.88 / 3.285Support & Résistance

Court Terme

Strong Bearish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

No Evidence

Sentiment

By Acuity

179 / 382Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Moyen

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Relay Therapeutics Inc

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.